Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Serous Adenocarcinoma: early-phase trial registry
3 of 9 indexed Ovarian Serous Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Ovarian Serous Adenocarcinoma: 9 US clinical trials tracked, 3 recruiting.
Ovarian Serous Adenocarcinoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition ovarian-serous-adenocarcinoma
OPEN 3 | RECR 33% | LATE 3 | EARLY 6 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Ovarian Serous Adenocarcinoma lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Serous Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Serous Adenocarcinoma is recruiting below its size-band peers.
3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ovarian Serous Adenocarcinoma research.
National Cancer Institute (NCI) accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Ovarian Serous Adenocarcinoma enrolment sits around 155 participants.
Median target enrolment is 155 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.
-
Ovarian Serous Adenocarcinoma research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
NCT04575935
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
NCT04919629
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
NCT05415709
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT01167712
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio
NCT04498117
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
NCT02502266
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT01116648
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT05451849
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
NCT02953457
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Serous Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Serous Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Serous Adenocarcinoma page
9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Ovarian Serous Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Ovarian Serous Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Serous Adenocarcinoma condition card totals 9 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.